Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid (Q37869505)

24 August 2017

1 reference

title

Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid (English)

1 reference

24 August 2017

4

Toni K Choueiri

1 reference

24 August 2017

Fabio A B Schutz

1

1 reference

24 August 2017

Joaquim Bellmunt

series ordinal

2

1 reference

24 August 2017

Jonathan E Rosenberg

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

28 April 2011

1 reference

Expert Opinion on Drug Safety

24 August 2017

published in

1 reference

24 August 2017

volume

10

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

645-653

1 reference

Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Mechanism of action of antitumor drugs that interact with microtubules and tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Vinflunine in the treatment of advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Second-line treatment of advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Phase II study of vinflunine in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Vinflunine -- an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

Phase II study of vinflunine in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.581660

10.1517/14740338.2011.581660

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference